Spotlight
Specialty
Partners
CME/CE
Transforming Outcomes in Hepatocellular Carcinoma: Expert Insights on Applying Evidence to Practice : Episode 4
HIMALAYA Study: Durvalumab + Tremelimumab in First-Line Treatment of Advanced HCC
Panelists review the HIMALAYA study, investigating durvalumab plus tremelimumab in patients with advanced HCC.
EP: 1.Patients With Intermediate Stage HCC Unsuitable for TACE
EP: 2.Patient Profile 1: Advanced HCC Treated with Durvalumab + Tremelimumab
EP: 3.Patients With Intermediate Stage HCC Suitable for TACE
Now Viewing
EP: 4.HIMALAYA Study: Durvalumab + Tremelimumab in First-Line Treatment of Advanced HCC
EP: 5.Selecting the Appropriate Frontline Treatment in Advanced HCC
EP: 6.Other Frontline Immunotherapy-based Combinations in Advanced HCC
EP: 7.Patient Profile 2: Advanced HCC Treated with Lenvatinib
EP: 8.Real-World Evidence for Lenvatinib in Advanced HCC
EP: 9.Treatment Selection in Patients Unsuitable for Atezolizumab + Bevacizumab
EP: 10.Patient Profile 3: Advanced HCC Treatment in Second Line and Beyond
Related Videos
Related Content
FDA Places Clinical Hold on Phase 1 Trial of XMT-2056 in HER2-expressing Solid Tumors
March 13th 2023
FDA Places Clinical Hold on Phase 1 Trial of XMT-2056 in HER2-expressing Solid Tumors
March 13th 2023
